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journal homepage: www.t jog-onl ine.comEditorialMaternal serum markers and preeclampsiaPreeclampsia is a pregnancy related condition identiﬁed by
hypertension and proteinuria after the 20th week of gestation
and complicates 2e8% of pregnancies worldwide, contributing to
a major cause of maternal, fetal, and neonatal morbidity and mor-
tality [1]. Although the pathogenesis of preeclampsia is not
entirely clear, preeclampsia is thought to develop as a result of
abnormal placental implantation (inadequate trophoblast invasion
and insufﬁcient spiral artery remodeling), followed by endothelial
dysfunction with subsequently resulting vasospasm, coagulop-
athy, or changes in capillary permeability and inﬂammatory
response; this underscores the importance of successfully estab-
lished circulation networks between the fetus and mother [2].
These established circulation networks require an ongoing
sequential and complicated processdangiogenesis [2]. The only
effective treatment for the abatement of preeclampsia symptoms
is delivery; therefore recent research has been focused on the
identiﬁcation of speciﬁc and sensitive biomarkers for early predic-
tion of preeclampsia, including several angiogenic, antiangiogenic,
inﬂammatory, biophysical (mean arterial pressure and uterine
artery Doppler) biomarkers, alone and in combination [3]. Howev-
er, all of them have been proposed for prediction, but predictive
values are limited hindering their use in clinical settings [3]. The
lack of mechanistic understanding makes early diagnosis and
prevention of preeclampsia nearly impossible [3]; therefore, any
biomarker reported to be useful for early diagnosis of preeclamp-
sia is welcome.
The study by Tuten et al [4] in the current issue of the Taiwa-
nese Journal of Obstetrics and Gynecology was conducted to inves-
tigate the potential biomarker of copeptin as a predictive model
of preeclampsia by examining the maternal serum levels of
copeptin in pregnant women with and without preeclampsia.
The authors found that the mean maternal serum copeptin levels
were higher in both early- and late-onset preeclampsia compared
with the control groups, and there was a statistically signiﬁcant
difference in early-onset preeclampsia, which was deﬁned as
having a preeclampsia before 34 weeks of gestation [4]. Copeptin,
a glycopeptide, makes up the C-terminal portion of prepro-
arginine vasopressin, which is the precursor protein of vaso-
pressin (AVP), a vasoactive neuropituitary hormone, and acts as
a carrier protein for AVP in conjunction with neurophysin II [5].
AVP plays a major role in the regulation of blood pressure and
water and maintains homeostasis of electrolytes, suggesting
that AVP may involve the pathophysiology of preeclampsia. How-
ever, the characteristics of AVP, including the short half-life and
instability, make reliable detection nearly impossible [5]. Copep-
tin is produced in a 1:1 ratio to AVP, has a longer half-life, andhttp://dx.doi.org/10.1016/j.tjog.2015.06.001
1028-4559/Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Publishedis more stable in serum, rendering it a clinically useful biomarker
of AVP secretion [5].
A few other studies have tested the association of maternal
serum levels of copeptin and occurrence of preeclampsia. Zulﬁkar-
oglu et al [6] found that plasma levels of copeptin were
0.31 ± 0.09 ng/mL in the normotensive pregnant group (n ¼ 32),
0.62 ± 0.16 ng/mL in the mild preeclamptic group (n ¼ 32), and
0.85 ± 0.18 ng/mL in the severe preeclamptic group (n ¼ 32;
p < 0.001), suggesting that increased maternal levels of copeptin
might be useful in the assessment of the severity of the disease
[6]. Both Foda et al [7] and Santillan et al [8] also supported the
above-mentioned ﬁndings; that higher maternal serum copeptin
levels were found in pregnant women with preeclampsia as
compared with normotensive pregnant women. Furthermore,
the sequential follow-up study by Santillan et al [8] further
showed that copeptin signiﬁcantly predicted preeclampsia
throughout gestation as early as the 6th week of gestation in the
ﬁrst trimester (area under the curve ¼ 0.90, p < 0.0001,
cutoff ¼ 811, sensitivity ¼ 88%, and speciﬁcity ¼ 81%), suggesting
that copeptin might be a novel, robust, and clinically useful
biomarker for the prediction of preeclampsia in very-early preg-
nancy [9]. In an animal model, chronic infusion of AVP during
pregnancy (24 ng per hour) is sufﬁcient to phenocopy preeclamp-
sia in C57BL/6J mice, causing pregnancy-speciﬁc hypertension,
renal glomerular endotheliosis, proteinuria, and intrauterine
growth restriction [8]. A study by Yeung et al [10], possibly biggest
sample-sized study, also conﬁrmed the correlation between
copeptin levels and preeclampsia and demonstrated that
increased copeptin was speciﬁcally predictive to the development
of preeclampsia.
Taken together, in the absence of effective treatment of pre-
eclampsia except delivery, the identiﬁcation of biomarkers for
early diagnosis of preeclampsia is of great importance and these
new biomarkers, such as proangiogenic placental growth factor,
antiangiogenic soluble fms-like tyrosine kinase 1, placental
protein 13, pregnancy-associated plasma protein A, copeptin,
cystatin C (measure of renal function), leucyl/cystinyl aminopepti-
dase, vasopressinase, many other microparticles and miRNA [9,11],
might help the development of new therapeutic targets that might
provide a more effective treatment option for this devastating
diseasedpreeclampsia.
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